Lipid Metabolism (Obesity)

11β-Hydroxysteroid dehydrogenase type 1 and 2 (11β-HSD1 and 2) are involved in the conversion of cortisone (C2755) to cortisol (H0135). 11β-HSD1 is expressed in adipose tissue. Overexpression of the enzyme and increased glutacorticoid levels results in lipid accumulation and an increase in visceral adipocytes [1]. Chronically elevated glucocorticoid levels cause Cushing’s syndrome, a disease caused by excessive cortisol production that triggers obesity, skin darkening, muscle weakness and fatigue. Thus, inhibiting 11β-HSD1 in adipose tissue could prove a viable therapy for treating both this disease and visceral obesity. Acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT1) acts as a key enzyme in the synthesis of triglycerides, the main form of excess calorie storage in fat. DGAT1 is also expressed in adipocytes and overexpression causes increased triglyceride levels. DGAT1-deficient mice exhibit increased insulin (I1507) and leptin (L4146) sensitivity and resistance to diet-induced obesity due to increased energy expenditure [2].
Since dietary fat constitutes 35-45% of energy intake, another therapeutic approach for the treatment of obesity is to inhibit the absorption of fat from the gut. Digestion of dietary fat occurs through the activation of two enzymes: gastric lipases, secreted in the stomach, and pancreatic lipases, secreted in the duodenum. Orlistat (O4139), a pancreatic and gastric lipase inhibitor approved by the FDA in 1999, reduces dietary fat absorption, thereby decreasing hydrolysis of ingested triglycerides [3]. Fatty acids and fatty acid metabolism may influence food intake and metabolic pathways through functions in the brain. Fatty acid synthase (FAS) inhibitors reduce food intake, body weight and body fat by altering the expression of hypothalamic neuropeptides such as NPY/AgRP, MCH (M4135), α-MSH (M2567) and POMC/CART. FAS substrates inhibit the mitochondrial enzyme carnitine palmitoyl transferase I (CPT I), increasing the levels of long chain acyl CoA derivatives levels [4]. Malonyl CoA (M4263) regulates CPT its formation and is regulated by acetyl CoA carboxylase (ACC). Mice deficient in this enzyme produce less malonyl CoA, which in turn increases CPT I and reduces long chain acyl CoA derivative levels, causing an increase in the rate of lipid oxidation [4].
1. Stewart, P.M. and Tomlinson, J.W., Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity. Trends Endocrinol. Metab., 13, 94-96 (2002).
2. Yu, Y.-H., et al., Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes. J. Biol. Chem, 277, 50876-50884 (2002).
3. Finer, N., Pharmacotherapy of obesity. Best Pract. Res. Clin. Endocrinol. Metab., 16, 717-742 (2002).
4. Flier, J.S., Obesity Wars: Molecular progress confronts an expanding epidemic. Cell, 116, 337-350 (2004).

Product #



Biochem/physiol Actions


Add to Cart

A6861   Acetyl-CoA carboxylase 2 human recombinant, expressed in Sf9 cells Acetyl-CoA Carboxylase (ACC) regulates the metabolism of fatty acids. This enzyme catalzes the formation of Malonyl CoA through the irreversible carboxylation of acetyl CoA. There are two main isoforms of Acetyl-CoA carboxylase expressed in mammals, Acetyl-CoA carboxylase 1 (ACACA) and Acetyl-CoA carboxylase 2 (ACACB). ACACA has broad tissue distribution but is enriched in tissues critical for fatty acid sythesis such as adipose tissue. ACACB is enriched in tissues such as skeletal muscle and heart that are critical for fatty acid oxidation.

The Acetyl-CoA Carboxylase enzymes are activated by citrate, glutamate, and dicarboxylic acids and negatively regulated by long and short chain fatty acyl CoAs. Because of thier roles in fatty acid metabolism and oxidation, ACACA and ACACB are therapeutic targets for treating obesity and metabolic syndrome disorders.
C2755 Cortisone ≥98% Cortisone (11 dehydro 17 hydroxycortico-sterone) is an anti-inflammatory glucocorticoid that delays wound healing after surgeries. It postpones the healing process by affecting the appearance of inflammatory cells, ground substance, fibroblasts, collagen, regenerating capillaries, and epithelial migration. Glucocorticoids have anti-inflammatory, anti-allergic and immunosuppressive properties and are extensively used in treatment and therapy.
Cortisone is a glucocorticoid; a corticosterone analog that has approximately twice the anti-inflammatory potency as corticosterone but much lower Na2+ retention potency.
chloroform: methanol (1:1): 50 mg/mL, clear to very slightly hazy, colorless to faintly yellow
F6932 Fucoxanthin carotenoid antioxidant Xanthophyll carotenoid pigment extracted from algae. Exhibits anticancer, antioxidant, anti-obesity and anti-inflammatory properties.
H0135 Hydrocortisone γ-irradiated, powder, BioXtra, suitable for cell culture Primary glucocorticoid secreted by the adrenal cortex. It has three times the anti-inflammatory potency of corticosterone but much lower Na2+ retention potency.
ethanol: 1 mg/mL, clear
I1507   Insulin human ≥95% (HPLC), semisynthetic, powder Insulin is important to maintain normal blood sugar levels. Insulin deficiency is associated with diabetes mellitus.
Two-chain polypeptide hormone produced by the β-cells of pancreatic islets. Its molecular weight is ~5800 Da. The α and β chains are joined by two interchain disulfide bonds. The α chain contains an intrachain disulfide bond. Insulin regulates the cellular uptake, utilization, and storage of glucose, amino acids, and fatty acids and inhibits the breakdown of glycogen, protein, and fat.
0.01 M HCl: 0.5 mg/mL, clear to slightly hazy, colorless
L4146 Leptin human ≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder Leptin is a hormone produced primarily in adipocytes, although leptin mRNA has also been identified in placenta and fetal tissues, gastric tissue and liver. Its primary site of action appears to be on neurons in the hypothalamus that are involved in regulating energy balance, appetite, and body weight. Leptin increases the production of nitric oxide in endothelial cells and stimulates angiogenesis in vitro and in vivo.
Human and mouse leptin share ~84% sequence identity.
Leptin is believed to play a role in normal pregnancy development.
Mutations in LEP (leptin) are linked with type-2 diabetes. Presence of high levels of leptin in plasma is related to adiposity.
M4263 Malonyl coenzyme A lithium salt ≥90% (HPLC) Coenzyme A functions as an acyl group carrier, acetyl-CoA. Malonyl Coenzyme A is a coenzyme A derivative that is utilized in fatty acid and polyketide synthesis and in the transport of α-ketoglutarate across the mitochondrial membrane. Malonyl CoA is formed by the Acetyl CoA Carboxylase-mediated carboxylation of acetyl CoA. Malonyl-CoA is exclusively used as the extender unit in the synthesis of bacterial aromatic polyketides.
Malonyl coenzyme A is a coenzyme A derivative that is utilized in fatty acid and polyketide synthesis and in the transport of α-ketoglutarate across the mitochondrial membrane. Malonyl CoA is formed by the Acetyl CoA Carboxylase-mediated carboxylation of acetyl CoA. Metabolism of glucose also yields malonyl coenzyme A. It allosterically blocks the action of carnitine palmitoyltransferase 1, which affects the transfer of long chain fatty acids into mitochondria. Inactivation of fatty acid synthase results in excess malonyl coenzyme A which leads to anorexia.
H2O: soluble 50 mg/mL protein, clear, colorless
M2567   Melanin Concentrating Hormone (6-17) ≥97% (HPLC), synthetic, lyophilized powder   water: 1.00-1.04 mg/mL, clear, colorless
O4139 Orlistat ≥98%, solid Orlistat impairs intestinal fat absorption and is effective in weight management. It is regarded as a safe drug for treating obesity. It delays the progression of type 2 diabetes mellitus especially in obese and improves glycemic parameters. Long term usage of orlistat results in improved weight reduction and it may not contribute in colorectal carcinogenesis.
Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.
DMSO: 19 mg/mL
M4135 α-Melanocyte stimulating hormone ≥97% (HPLC) Hormone that stimulates melanogenesis; facilitates learning and memory; affects inflammatory and immune responses and peripheral nerve regeneration.
Pituitary hormone which causes darkening skin pigmentation from amphibians to humans. In mammals, it can also have behavioral effects on learning, attention, and memory.
α-Melanocyte-stimulating hormone (α-MSH) acts as an anti-inflammatory agent via down regulating the production and activity of the pro-inflammatory cytokines interleukin-1 (IL-1), tumor necrosis factor (TNF)-α and IL-6 expressed in various cells of the immune system. It also controls the nitric oxide production associated with inflammation. α−MSH inhibits nuclear factor-κB (NF-κB)-dependent gene transcription and NF-κB pathway induced by TNF and other inflammatory agents. This activity of α-MSH is mediated through the production of cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA) enzyme. α–MSH functions as a potent therapeutics for various conditions resulted through NF-κB activation including, inflammatory diseases, human immunodeficiency virus (HIV) replication in AIDS (acquired immunodeficiency syndrome), and septic shock. α-MSH has an essential role to play in melanin production in animals. α-MSH regulates development of several skin diseases, including cutaneous inflammation and hyper-proliferative skin diseases.
water: 1.00-1.04 mg/mL, clear, colorless